Payment overview · 2025
General Payments
$224.13
6 reported records · 3 companies
Healthcare provider profile · identity verified
Patrick Daniel Fleming, MD
Allopathic & Osteopathic Physicians|Family Medicine · VALPARAISO, IN · NPI 1669433256
Verified facts
What the public records show
CMS Open Payments records show Patrick Daniel Fleming, MD received $224.13 in general payments during 2025 across 6 reported records.
HEARTFLOW, INC. accounted for 55.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $125.00 | 55.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.70 | 25.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.43 | 18.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.13 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.70 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.43 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 516 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 100 |
| Omeprazole | Omeprazole | 305 | 90 |
| Losartan Potassium | Losartan Potassium | 273 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 268 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 202 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 68 |
| Simvastatin | Simvastatin | 179 | 52 |
| Valsartan | Valsartan | 179 | 53 |
| Atenolol | Atenolol | 162 | 43 |
| Lisinopril | Lisinopril | 152 | 46 |
| Potassium Chloride | Potassium Chloride | 152 | 43 |
| Metformin Hcl Er | Metformin Hcl | 145 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 36 |
| Methylprednisolone | Methylprednisolone | 124 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 57 |
| Metformin Hcl | Metformin Hcl | 122 | 34 |
| Glimepiride | Glimepiride | 121 | 32 |
| Allopurinol | Allopurinol | 117 | 34 |
| Furosemide | Furosemide | 111 | 27 |
| Trazodone Hcl | Trazodone Hcl | 105 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 27 |
| Gabapentin | Gabapentin | 100 | 29 |
| Jardiance | Empagliflozin | 97 | 24 |
| Chlorthalidone | Chlorthalidone | 95 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 26 |
| Montelukast Sodium | Montelukast Sodium | 86 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 20 |
| Meloxicam | Meloxicam | 78 | 24 |
| Finasteride | Finasteride | 73 | 23 |
| Tramadol Hcl | Tramadol Hcl | 72 | 17 |
| Alprazolam | Alprazolam | 66 | 18 |
| Ozempic | Semaglutide | 66 | 16 |
| Sertraline Hcl | Sertraline Hcl | 66 | 19 |
| Farxiga | Dapagliflozin Propanediol | 65 | 19 |
| Famotidine | Famotidine | 64 | 15 |
| Synthroid | Levothyroxine Sodium | 64 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 19 |
| Clonazepam | Clonazepam | 55 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 18 |
| Celecoxib | Celecoxib | 50 | suppressed |
| Eliquis | Apixaban | 50 | 11 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 20 |
| Alendronate Sodium | Alendronate Sodium | 41 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Prednisone | Prednisone | 41 | 16 |
| Ezetimibe | Ezetimibe | 39 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 14 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 12 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.13 · 6 records | HEARTFLOW, INC. | AIRSUPRA, FFRct, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error